HilleVax reported a net loss of $6.1 million for the first quarter ended March 31, 2025, a significant improvement from a $46.8 million loss in the same period of 2024. The company's cash, cash equivalents, and marketable securities totaled $159.5 million as of March 31, 2025.
Research and development (R&D) expenses dramatically decreased to $2.0 million in Q1 2025, compared to $26.0 million in Q1 2024, primarily due to lower clinical development costs. General and administrative (G&A) expenses also decreased to $5.6 million from $8.5 million in the prior year's quarter, reflecting lower personnel-related costs.
Other income for the first quarter 2025 was $1.5 million, down from $3.0 million in Q1 2024, driven by lower accretion of marketable securities. The company continues to explore the potential for continued development of its norovirus vaccine candidates in adults and other strategic alternatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.